Awad R, Avital A, Sosnik A. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. Acta Pharm Sin B. 2023. https://doi.org/10.1016/j.apsb.2022.07.003

Article  PubMed  Google Scholar 

Huang Q, Chen Y, Zhang W, Xia X, Li H, Qin M, et al. Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases. J Control Release. 2024. https://doi.org/10.1016/j.jconrel.2023.12.054

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, et al. Intranasal drug delivery: the interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev. 2024. https://doi.org/10.1016/j.addr.2024.115196

Article  PubMed  PubMed Central  Google Scholar 

Upadhyay R, Ghosh P, Desavathu M. Advancement in the Nose-to-Brain drug delivery of FDA-approved drugs for the better management of depression and psychiatric disorders. Int J Pharm. 2024. https://doi.org/10.1016/j.ijpharm.2024.124866

Article  PubMed  Google Scholar 

Costa CP, Moreira JN, Sousa Lobo JM, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharm Sin B. 2021. https://doi.org/10.1016/j.apsb.2021.02.012

Article  PubMed  PubMed Central  Google Scholar 

Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018. https://doi.org/10.1016/j.ejpb.2018.05.009

Article  PubMed  Google Scholar 

Chung S, Peters JM, Detyniecki K, Tatum W, Rabinowicz AL, Carrazana E. The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav Rep. 2023. https://doi.org/10.1016/j.ebr.2022.100581

Article  PubMed  Google Scholar 

Rezaee S, Al-Majdoub ZM, Galetin A, Rostami-Hodjegan A, Ogungbenro K. Challenges and opportunities for incorporating physiological information into Pharmacokinetic models of intranasal drug delivery to the brain: A review of the current status and future trajectories. Mol Pharm. 2025. https://doi.org/10.1021/acs.molpharmaceut.5c00297

Article  PubMed  Google Scholar 

Costa C, Moreira JN, Amaral MH, Sousa Lobo JM, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release. 2019. https://doi.org/10.1016/j.jconrel.2018.12.049

Article  PubMed  Google Scholar 

Lee D, Minko T. Nanotherapeutics for Nose-to-Brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13122049

Article  PubMed  PubMed Central  Google Scholar 

Gänger S, Schindowski K. Tailoring formulations for intranasal Nose-to-Brain delivery: A review on Architecture, Physico-Chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018. https://doi.org/10.3390/pharmaceutics10030116

Article  PubMed  PubMed Central  Google Scholar 

Ahmad S, Khan I, Pandit J, Emad NA, Bano S, Dar KI, et al. Brain targeted delivery of carmustine using Chitosan coated nanoparticles via nasal route for glioblastoma treatment. Int J Biol Macromol. 2022. https://doi.org/10.1016/j.ijbiomac.2022.08.210

Article  PubMed  PubMed Central  Google Scholar 

Rassu G, Soddu E, Posadino AM, Pintus G, Sarmento B, Giunchedi P, et al. Nose-to-brain delivery of BACE1 SiRNA loaded in solid lipid nanoparticles for alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017. https://doi.org/10.1016/j.colsurfb.2017.01.031

Article  PubMed  Google Scholar 

Yang X, Yang W, Xia X, Lei T, Yang Z, Jia W, et al. Intranasal delivery of BACE1 SiRNA and Rapamycin by dual targets modified nanoparticles for alzheimer’s disease therapy. Small. 2022. https://doi.org/10.1002/smll.202203182

Article  PubMed  PubMed Central  Google Scholar 

Zhang C, Chen J, Feng C, Shao X, Liu Q, Zhang Q, et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat alzheimer’s disease. Int J Pharm. 2014. https://doi.org/10.1016/j.ijpharm.2013.11.049

Article  PubMed  Google Scholar 

Chater PI, Wilcox MD, Pearson JP. Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems. Adv Drug Deliv Rev. 2018. https://doi.org/10.1016/j.addr.2017.12.006

Article  PubMed  Google Scholar 

Xu Y, Ye X, Du Y, Yang W, Tong F, Li W, et al. Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged β-amyloid nanoscavenger for alzheimer’s disease therapy. Acta Pharm Sin B. 2025. https://doi.org/10.1016/j.apsb.2025.02.035

Article  PubMed  PubMed Central  Google Scholar 

Wang G, Zhai Z, Wang W, Xia X, Guo H, Yue X, et al. Tailored Borneol-Modified lipid nanoparticles nasal spray for enhanced Nose-to-Brain delivery to central nervous system diseases. ACS Nano. 2024. https://doi.org/10.1021/acsnano.4c08279

Article  PubMed  PubMed Central  Google Scholar 

Yue X, Guo H, Wang G, Li J, Zhai Z, Wang Z, et al. A tailored phytosomes based nose-to-brain drug delivery strategy: silver bullet for alzheimer’s disease. Bioactive Mater. 2025. https://doi.org/10.1016/j.bioactmat.2024.09.039

Article  Google Scholar 

Yang H, Mu W, Wei D, Zhang Y, Duan Y, Gao JX, et al. A novel targeted and High-Efficiency nanosystem for combinational therapy for alzheimer’s disease. Adv Sci (Weinh). 2020. https://doi.org/10.1002/advs.201902906

Article  PubMed  PubMed Central  Google Scholar 

Li J, Peng H, Zhang W, Li M, Wang N, Peng C, et al. Enhanced Nose-to-Brain delivery of combined small interfering RNAs using Lesion-Recognizing nanoparticles for the synergistic therapy of alzheimer’s disease. ACS Appl Mater Interfaces. 2023. https://doi.org/10.1021/acsami.3c08756

Article  PubMed  PubMed Central  Google Scholar 

Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014. https://doi.org/10.1016/j.jconrel.2014.06.053

Article  PubMed  Google Scholar 

Nguyen TT, Duong VA. Advancements in Nanocarrier Systems for Nose-to-Brain Drug Delivery. Pharmaceuticals (Basel). 2025. https://doi.org/10.3390/ph18050615

Al Asmari AK, Ullah Z, Tariq M, Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther. 2016. https://doi.org/10.2147/dddt.S93937

Article  PubMed  PubMed Central  Google Scholar 

Khot KB, Gopan DSS, Deshpande G, Shastry NS, Bandiwadekar P. Enhancing selegiline hydrochloride efficacy: box Behnken-optimized liposomal delivery via intranasal route for parkinson’s disease intervention. J Liposome Res. 2024. https://doi.org/10.1080/08982104.2024.2336549

Article  PubMed  Google Scholar 

Katamesh AA, Abdel-Bar HM, Break MKB, Hassoun SM, Subaiea GM, Radwan A, et al. Tailored intranasal albumin caged Selegiline-α synuclein SiRNA liposome with improved efficiency in parkinson’s model. Pharmaceutics. 2025. https://doi.org/10.3390/pharmaceutics17020243

Article  PubMed  PubMed Central  Google Scholar 

Nguyen TT, Maeng HJ. Pharmacokinetics and pharmacodynamics of intranasal solid lipid nanoparticles and nanostructured lipid carriers for Nose-to-Brain delivery. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14030572

Article  PubMed  PubMed Central  Google Scholar 

Bhatt R, Singh D, Prakash A, Mishra N. Development, characterization and nasal delivery of Rosmarinic acid-loaded solid lipid nanoparticles for the effective management of huntington’s disease. Drug Deliv. 2015. https://doi.org/10.3109/10717544.2014.880860

Article  PubMed  Google Scholar 

Nematalla HA, Elharoun M, Bargash SN, Abd-Alhaseeb MM, Sharafeldin HA, Zewail M, et al. Novel Nose-to-brain delivery of Carbenoxolone via mucoadhesive solid lipid nanoparticles for parkinson’s symptoms management: in vitro and in vivo evaluation in a rotenone-induced rat model. Int J Pharm. 2025. https://doi.org/10.1016/j.ijpharm.2025.125197

Article  PubMed  Google Scholar 

Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed. 2011. https://doi.org/10.2147/ijn.S15881

Article